Search
SOLACI Congress
HomeStructural heart diseaseOther

Other

View Category

Other

Prognosis After Pacemaker Implantation in Alcohol Septal Ablation

One of the main complications of alcohol septal ablation (ASA) is the alteration in the conduction system,...
solaci -
Learn More
Other

TCT 2022 | AMULET IDE: Events at 3 Years Using the AMULET Appendage Closure Device

The aim of this study was to assess the 3-year efficacy for the endpoints of the AMULET...
solaci -
Learn More
Other

Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising...
solaci -
Learn More
Day 2

SOLACI-SOCIME 2022 | Cierre de CIA tipo seno venoso superior: ¿Un nuevo invitado en la mesa? by Dr. Juan Pablo Sandoval

Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult...
solaci -
Learn More
Other

Peridevice Leak in Left Atrial Appendage Closure: more than one value to take into account

According to several registries, incomplete left atrial appendage (LAA) closure has been observed in up to 30%...
solaci -
Learn More
Other

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart...
solaci -
Learn More
Other

TRAPEUR Registry: Thrombus Trapping with Left Atrial Appendage Closure Device

Left atrial appendage closure (LAAC) devices are a good alternative for the prevention of systemic thromboembolism in...
solaci -
Learn More
Other

Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Dr. Carlos Fava - 0
Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

Institutional News

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy